Indiana University Trials Maintenance Zanzalintinib with Oral Etoposide in Relapsed Metastatic GCT

This open-label phase I/II study evaluates the safety and optimal dosing of zanzalintinib, a c-Met/VEGFR inhibitor, in combination with oral etoposide following high-dose chemotherapy and PBSCT in patients with relapsed metastatic germ-cell tumors. The trial includes a safety lead-in, followed by a dose expansion phase to further explore efficacy in both non-seminomatous and other relapsed GCT cases.